Tectonic Advisors LLC Purchases 3,322 Shares of AbbVie Inc. $ABBV

Tectonic Advisors LLC boosted its position in shares of AbbVie Inc. (NYSE:ABBV) by 6.6% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 53,388 shares of the company’s stock after acquiring an additional 3,322 shares during the quarter. Tectonic Advisors LLC’s holdings in AbbVie were worth $12,361,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of ABBV. Norges Bank purchased a new position in shares of AbbVie in the second quarter worth approximately $4,288,200,000. Laurel Wealth Advisors LLC raised its position in AbbVie by 18,384.4% in the second quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock worth $1,059,141,000 after acquiring an additional 5,675,095 shares during the period. Assenagon Asset Management S.A. boosted its stake in shares of AbbVie by 550.9% during the 2nd quarter. Assenagon Asset Management S.A. now owns 4,332,054 shares of the company’s stock worth $804,116,000 after acquiring an additional 3,666,521 shares during the last quarter. Vanguard Group Inc. grew its position in shares of AbbVie by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after acquiring an additional 3,380,842 shares during the period. Finally, Kingstone Capital Partners Texas LLC purchased a new stake in shares of AbbVie in the 2nd quarter worth $581,817,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Hsbc Global Res raised AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, December 10th. Guggenheim boosted their price objective on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research note on Monday, October 20th. BMO Capital Markets raised their target price on shares of AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a research note on Friday, September 12th. Finally, Scotiabank began coverage on shares of AbbVie in a report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price target on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $245.84.

AbbVie Trading Up 0.3%

Shares of ABBV opened at $229.26 on Friday. The business’s 50 day moving average is $226.69 and its 200 day moving average is $213.74. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The company has a market capitalization of $405.19 billion, a PE ratio of 173.68, a price-to-earnings-growth ratio of 0.96 and a beta of 0.36.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same period in the prior year, the company posted $3.00 EPS. The firm’s revenue for the quarter was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities research analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.0%. AbbVie’s dividend payout ratio is 496.97%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.